参芪扶正注射液辅助治疗中晚期原发性肝癌临床研究

Clinical Study of Shenqi Fuzheng Injection in Adjuvant Treatment for Advanced Primary Liver Cancer

目的:观察参芪扶正注射液辅助治疗中晚期原发性肝癌对患者肝功能和细胞免疫功能的影响。方法:选取160例中晚期原发性肝癌患者为研究对象,按照随机数字表法分为联合组和常规组,每组80例。常规组采用经导管肝动脉化疗栓塞(TACE)治疗,联合组在此基础上辅以参芪扶正注射液治疗。观察2组治疗前后肝功能、细胞免疫功能和中医症状积分的变化。结果:治疗后,2组丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)水平均较治疗前降低(P <0.05),联合组ALT、AST、ALP水平均低于常规组(P <0.05)。治疗后,2组CD4^+、NK值均较治疗前升高(P <0.05);CD8^+、CD4^+/CD8^+值均较治疗前降低(P <0.05);联合组CD4^+、NK值均高于常规组(P <0.05),CD8^+、CD4^+/CD8^+值低于常规组(P <0.05)。与治疗前比较,治疗后联合组4项中医症状积分及常规组气短、腹胀积分均降低(P <0.05)。治疗后联合组纳差、腹胀、乏力积分均低于常规组(P <0.05)。结论:参芪扶正注射液辅助治疗中晚期原发性肝癌,能有效改善患者的肝功能指标,提高细胞免疫功能,改善腹胀、乏力等中医症状,值得临床推广。

Objective: To observe the clinical effect of Shenqi Fuzheng injection in adjuvant treatment for advanced primary liver cancer, and its effect on the liver function and cellular immune function of patients. Methods: Selected 160 cases of patients with advanced primary liver cancer as study subjects,and divided them into the combination group and the routine group randomly, 80 cases in each group. The routine group received transcatheter arterial chemoembolization(TACE), while the combination group additionally received Shenqi Fuzheng injection. Observed the changes of liver function, cellular immune function and Chinese medicine symptom scores before and after treatment in both groups. Results: After treatment, the levels of alanine aminotransferase(ALT) aspartate aminotransferase(AST) and alkaline phosphatase(ALP) in both groups were lower than those before treatment(P < 0.05), and the levels of ALT, AST and ALP in the combination group were lower than those in the routine group(P < 0.05). After treatment, the indexes of CD4^+ and NK in both groups were higher than those before treatment(P < 0.05),and the indexes of CD8^+ and CD4^+/CD8^+ were lower than that before treatment(P < 0.05);the indexes of CD4^+ and NK in the combination group were higher than those in the routine group(P < 0.05), and the indexes of CD8^+ and CD4^+/CD8^+ were lower than that in the routine group(P < 0.05). After treatment, Chinese medicine scores of 4 items in the combination group and scores of short breath and abdominal distention in the routine group were all lower than those before treatment(P < 0.05). Scores of poor appetite,abdominal distention and hypodynamia in the combination group were all lower than those in the routine group(P < 0.05). Conclusion: Shenqi Fuzheng injection in adjuvant treatment for advanced primary liver cancer can effectively improve the indexes of liver function of patients,enhance cellular immune function, and relieve such Chinese medicine symptoms as abdominal distention and hypodynamia. It is worthy of clinical promotion.